D4 Labs, LLC in Pacific Grove, CA announced today that it has successfully prepared an adjuvanted inactivated Diphtheria toxoid, Tetanus toxoid, and acellular Pertussis (DTaP) vaccine using its SubATVax™ technology, utilizing the same formulation in its recently issued U.S. Patent #11911461.
Dr. David Craig Wright, the Chief Scientific Officer at D4 Labs, LLC said the following:
“We have spent the last four years developing SubATVax™ technology. Our hypothesis was that we could develop refrigerated, adjuvanted vaccines, which could be administered subcutaneously in a small volume (300 μL) in a one-or two-dose format. Several approved vaccines require up to five injections for optimal immunity. One of those is the DTaP vaccine used in the United States. We have successfully adjuvanted a DTaP vaccine with our SubATVax™ technology. Our SubATVax™ vaccines can be administered in small volumes (300 microliters) subcutaneously through 25-gauge needles. We have also filled needleless syringes with 250 microliters of our adjuvanted vaccines. We encourage other companies, government laboratories, and academic
centers to contact us about utilizing our technology with either approved vaccines, like DTaP, or new vaccines in development.”
For more information, call Dr. Wright at (831) 664-5464 or email davidwright@d4abs.com